Catalyst Wire Dossier Catalyst Wire Dossier
EMA withdrawal · 2012-11-23

EMA Refused: Elelyso (taliglucerase alfa) — Pfizer Ltd.

View source ↗

Summary

The EMA refused the marketing authorization for Elelyso (taliglucerase alfa) by Pfizer Ltd., in the Gaucher disease indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ELELYSO (TALIGLUCERASE ALFA)

Snippet

Status: Refused. Therapeutic area: Gaucher Disease. MAH: Pfizer Ltd.. Decision date: 29/10/2012. Orphan medicine